40 results on '"Saiag, Philippe"'
Search Results
2. Association of baseline corticosteroid treatment with outcomes for patients (pts) with BRAF-mutant melanoma brain metastases (MBMs) in COMBI-MB treated with dabrafenib and trametinib (DT).
3. Efficacy and tolerance of systemic therapies in metastatic melanoma of unknown primary versus known cutaneous: A multicenter retrospective study from the MelBase French Cohort.
4. Differential gradients of efficacy of immunotherapy according to the sun-exposure pattern of the site of occurrence of primary melanoma: A multicenter prospective cohort study (MELBASE).
5. Second primary melanoma in advanced melanoma patients treated with anti-PD-1 monoclonal antibodies.
6. Recommendations for an Effective Follow-Up Strategy in Melanoma Patients Should Be Tailored to the Investigations Performed During Initial Staging
7. Plasma concentrations of dabrafenib and trametinib (PCD/T) monitoring in advanced BRAFV600mut melanoma patients.
8. Efficacy of hypofractionated radiotherapy (Rx) in melanoma patients who failed anti-PD-1 monotherapy: Assessing the abscopal effect.
9. Progression and hyperprogression after anti-PD1 therapy for unresectable stage III or IV melanoma patients.
10. Phase II Study of Pembrolizumab As First-Line, Single-Drug Therapy for Patients With Unresectable Cutaneous Squamous Cell Carcinomas.
11. Elderly patient’s tolerance and efficacy for MAP-kinase inhibitors in a French melanoma real-life cohort.
12. Impact of simultaneous radiotherapy in melanoma patients treated with pembrolizumab in the French early access program.
13. Immune checkpoint inhibitors and stereotactic radiosurgery (SRS) in melanoma brain metastases.
14. Discontinuation of anti-PD-1 mAb after complete response in advanced melanoma pts.
15. Outcomes of elderly treated with pembrolizumab for metastatic melanoma comparing with younger patients.
16. Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: First results of a multicenter, open-label, phase 2 trial (VISMONEO study).
17. HORIZON: A French descriptive cohort of 663 patients treated for melanoma with pembrolizumab with a focus on the mucosal subgroup (n=59).
18. Ipilimumab combined with stereotactic radiosurgery in melanoma patients with brain metastases: A multicenter, open label, phase 2 trial.
19. Role of time to switch from ipilimumab to anti-PD1 in anti-PD1 efficacy within the French national cohort, MelBase.
20. Micro- and macro-metastatic disease kinetics: Results from the French cohort Melbase.
21. Efficacy of combined hypofractionated radiotherapy and anti-PD-1 monotherapy in patients with melanoma.
22. COMBI-MB: A phase II study of combination dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600–mutant (mut) melanoma brain metastases (MBM).
23. Resistances to vismodegibs in a French case series of 207 patients with locally advanced basal cell carcinoma.
24. Immunotherapy-treated melanoma brain metastases within the French national cohort, MelBase.
25. Melapred: first susceptibility test to sporadic melanoma in daily dermatological practice.
26. Frequent allelic imbalance in NRAS mutant melanomas.
27. Phase II multicentric uncontrolled national trial assessing the efficacy of nilotinib in the treatment of advanced melanomas with c-KIT mutation or amplification: Results of the pharmacodynamic study.
28. Treatment of dermatofibrosarcoma protuberans (DFSP) with fixed Mohs micrographic surgery (f-MMS).
29. Follow-up of a French national cohort of melanoma stage IV and unresectable stage III patients, MelBase.
30. First-in-human phase I study of the DNA repair inhibitor DT01 in combination with radiotherapy in patients with in transit melanoma.
31. Comparing PD-L1 scores for predicting pembrolizumab efficacy in first-line treatment of unresectable cutaneous squamous cell carcinomas.
32. Avelumab as second-line or later (2L+) treatment in patients (pts) with metastatic Merkel cell carcinoma (mMCC): Analysis of real-world outcomes in France using the CARADERM registry and the French national healthcare database.
33. Efficacy of adjuvant therapy in patients (pts) with AJCC v8 stage IIIA cutaneous melanoma.
34. Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: Impact on tumor response and tolerance.
35. A phase II study to assess vismodegib in the neoadjuvant treatment of locally advanced basal cell carcinoma (laBCC): The Vismodegib Neoadjuvant (VISMONEO) study.
36. Personal melanoma risk awareness versus intrinsic risk.
37. Prognostic value of BRAFV600 mutations in melanoma patients after resection of metastatic lymph nodes.
38. Vemurafenib (V) in BRAF V600E metastatic melanoma (mM): Analysis of 507 patients (pts) enrolled in the French temporary authorization for use (ATU).
39. Comparison of sun protection modalities in parents and children.
40. Sun exposure profile in the French population: Results of the EDIFICE melanoma survey.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.